TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

cMet is a well‐characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody–drug conjugates (ADCs). However, the clinical benefit from cMet‐targeted therapy has been limited. We developed a novel cMet‐targeted ‘third‐g...

詳細記述

保存先:
書誌詳細
出版年:Mol Oncol
主要な著者: Gymnopoulos, Marco, Betancourt, Oscar, Blot, Vincent, Fujita, Ryo, Galvan, Diana, Lieuw, Vincent, Nguyen, Sophie, Snedden, Jeanette, Stewart, Christine, Villicana, Jose, Wojciak, Jon, Wong, Eley, Pardo, Raul, Patel, Neki, D’Hooge, Francois, Vijayakrishnan, Balakumar, Barry, Conor, Hartley, John A., Howard, Philip W., Newman, Roland, Coronella, Julia
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2019
主題:
Research Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6944112/
https://ncbi.nlm.nih.gov/pubmed/31736230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12600
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料